Karen Webb
Nurse Practitioner · Alamo, TNNPI 1902819501
Payments from drug & device makers
Across 235 payments — averaging $17.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$862
- AbbVie$788
- Otsuka America Pharmaceutical, Inc.$411
- Lilly USA, LLC$296
- GSK$252
- Pfizer$230
- plus $1K from 24 others
What the payments were for
- Food & beverage$4,103100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 50 | $862 |
| AbbVie | 48 | $788 |
| Otsuka America Pharmaceutical, Inc. | 22 | $411 |
| Lilly USA, LLC | 19 | $296 |
| GSK | 13 | $252 |
| Pfizer | 15 | $230 |
| AstraZeneca | 8 | $211 |
| Amgen | 10 | $154 |
| Lundbeck LLC | 7 | $120 |
| Dexcom, Inc. | 5 | $106 |
| Ardelyx, Inc. | 5 | $79 |
| Sumitomo Pharma America, Inc. | 4 | $75 |
| Nestle Healthcare Nutrition Inc. | 3 | $67 |
| Aimmune Therapeutics, Inc. | 3 | $52 |
| Merck | 3 | $44 |
| Phathom Pharmaceuticals, Inc. | 3 | $42 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $35 |
| Sunovion Pharmaceuticals Inc. | 2 | $34 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $32 |
| Astellas Pharma US Inc | 1 | $25 |
| Neurocrine Biosciences, Inc. | 1 | $24 |
| Neurelis, Inc. | 1 | $22 |
| Axsome Therapeutics, Inc. | 1 | $21 |
| Boehringer Ingelheim | 1 | $20 |
| SK Life Science, Inc. | 1 | $19 |
| Exact Sciences | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Johnson & Johnson | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Novartis | 1 | $15 |
How this compares
$4,103 in reported general payments places this provider in the 85th percentile of 2,662 nurse practitioner providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 60 | $58,144 |
| RybelsusSemaglutide | 34 | $41,087 |
| JardianceEmpagliflozin | 31 | $32,971 |
| EliquisApixaban | 21 | $23,819 |
| RexultiBrexpiprazole | 14 | $22,182 |
| OzempicSemaglutide | 15 | $21,867 |
| LinzessLinaclotide | 20 | $16,642 |
| XareltoRivaroxaban | 17 | $11,066 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $10,741 |
| FarxigaDapagliflozin Propanediol | 18 | $10,476 |
| TrintellixVortioxetine Hydrobromide | 12 | $5,315 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 119 | $2,914 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 15 | $2,879 |
| Omeprazole | 200 | $2,147 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 85 | $1,711 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus, Ozempic | $862 | $62,95349 claims |
| MerckJanuvia | $44 | $58,14460 claims |
| Boehringer IngelheimJardiance | $20 | $32,97131 claims |
| PfizerEliquis | $230 | $23,81921 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $411 | $22,18214 claims |
| AbbVieLinzess, Synthroid | $788 | $18,12236 claims |
| Johnson & JohnsonXarelto | $16 | $11,06617 claims |
| GSKTrelegy Ellipta | $252 | $10,74115 claims |
| AstraZenecaFarxiga | $211 | $10,47618 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $19 | $5,31512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,662 nurse practitioner providers in Tennessee.
Other nurse practitioner in Alamo
- Amy HatcherMurfreesboro$1.1M
- Karen RodenKnoxville$265K
- Susan UtleyNashville$194K
- Whitney EricksonMemphis$159K
- Erica HembreeKnoxville$125K
- Brooke FaughtNashville$89K
- Lauren WelchNashville$71K
- Cara StoutKingsport$71K
- S Marie HamiltonOoltewah$64K
- Cynthia WilsonChattanooga$62K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.